Patents by Inventor Guifang ZHOU

Guifang ZHOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody specifically binding to human plasmalemma vesicle-associated protein PV-1, preparation and use thereof
    Patent number: 11666659
    Abstract: Disclosed herein is a monoclonal antibody or a derivative thereof that specifically binds to human plasmalemma vesicle-associated protein (PLVAP, PV-1), including antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable medicament, administered alone or combined with other medications such as anti-VEGF monoclonal antibody and the like, for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: June 6, 2023
    Assignee: HUALAN GENETIC ENGINEERING CO., LTD.
    Inventors: Xiaoqi Song, Zui Chen, Hongqun Hu, Guifang Zhou, Jinling Fan, Qunmin Zhou
  • MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO HUMAN PLASMALEMMA VESICLE-ASSOCIATED PROTEIN PV-1, PREPARATION AND USE THEREOF
    Publication number: 20210000969
    Abstract: Disclosed herein is a monoclonal antibody or a derivative thereof that specifically hinds to human plasmalemma vesicle-associated protein (PLVAP, PV-1), including antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable medicament, administered alone or combined with other medications such as anti-VEGF monoclonal antibody and the like, for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 7, 2021
    Applicant: HUALAN GENETIC ENGINEERING CO., LTD.
    Inventors: Xiaoqi SONG, Zui CHEN, Hongqun HU, Guifang ZHOU, Jinling FAN, Qunmin ZHOU